-
Most Popular
Healthcare Stocks
Healthcare encompasses a wide range of organized services to prevent, treat, and diagnose medical needs and mental illnesses. The $336 billion market is expected to grow at a compound annual growth rate of 8% until 2030, demonstrating the necessity of adequate healthcare. Healthcare companies, ranging from retailer CVS to insurance giant UnitedHealth, provide these services to a massive customer base.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
7 Dependable Dividend Stocks for Long-Term Income
Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets.
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.
Other industries you might be interested in
Recent Healthcare Stocks Articles
Decriminalization Won’t Pass the Senate, and Cronos Will Come Back Down
This morning, I am recommending a bearish trade on Cronos Group, Inc. (NASDAQ:CRON), the vertically integrated cannabis company.
Don’t Buy Cronos Stock on the U.S. House Committee Vote
CRON stock should become an eventual winner for investors, but the rally sparked by the vote in the U.S. House will likely not last.
The Smart Money Is Waiting for Cannabis Stocks to Stabilize
It makes sense to stay on the sidelines while cannabis stocks deal with supply issues. Waiting for stability is the best play right now.
Aurora Stock Pops on Hope of Federal Marijuana Legalization
ACB stock rallied with a bill that would decriminalize marijuana at the federal level up for a vote. Analysts are upbeat on Aurora stock.
Trade of the Day: Canopy Growth Leaves Bullish Mark on the Charts
Cannabis stocks like CGC stock rallied on November 20th, which in turn left a notable bullish mark behind on the chart. All else being equal this now calls for more upside in the stock.
As Canopy Growth Stock Stalls, Pot Investors Mull What Will Happen Next?
Canopy Growth faces plenty of tough problems ahead. So too, do its competitors. When will outsized growth return to CGC?
We’re One Step Closer to the Ultimate Catalyst for Cannabis Stocks
Even as stocks are under pressure, cannabis continues to proceed down the path toward full legalization. It is closer now than ever.
Here’s How to Trade Aphria Stock Without Getting Smoked
If you’re looking for a cannabis standout off and on the price chart, Aphria stock is delivering in more than one way for investors.
7 Catalysts Pointing to Massive Potential in Chinese Biotech Stocks
Even beyond China’s strong support of biotech, there are seven more reasons why investing in the sector will be one of the best wealth-building opportunities of the next 20 years.
Chinese Biotech Stocks: The 100X Play as Big Pharma Money Moves In
Investing in Chinese biotech stocks today is similar to getting into U.S. biotech back in the 1990s.
Aphria Stock Has the Best Chances of Soaring High in the Pot Market
Aphria has a strong brand, independent management and plenty of cash on the books to fund its expansion. How will Aphria stock fare next?
The Manitoba Harvest Acquisition Saved Tilray Stock This Quarter
Tilray’s acquisition of Manitoba Harvest should help Tilray stock. TLRY stock may perform better than other marijuana stocks.
Ocugen Stock Is Nothing More than a Risky Trade on Even-riskier Biotech
Ocugen gave rise to OCGN stock through a reverse merger with Histogenics. But despite this confusing deal, it really didn't do much for either company in the end.
Investors Can Still Get High on American Marijuana Stocks
Tune into 'Moneyline' with Matt McCall for more on CRON stock, other cannabis plays and three under-the-radar stocks you should watch.
Will It Get Worse Before It Gets Better for Hexo Stock?
As HEXO stock has overpromised and underdelivered in recent months. the Hexo stock price has declined very rapidly.
‘Cannabis 2.0’ May Not Be Enough to Save Canopy Growth Stock
"Cannabis 2.0" could be the catalyst to save CGC stock. But other factors remain at play. Tread carefully before buying Canopy Growth stock.
Why Aurora Cannabis Stock Isn’t Worth a Hit Before Earnings
Don’t expect Aurora Cannabis to pull an ace from its sleeve when it reports earnings this evening. Here's why ACB stock should be avoided.
Q3 Numbers Show Why Cronos Stock May Not Rebound in the Short Term
CRON stock will head way higher in the long run. But, the long-term rebound won't start until today's weak profit trends improve.
